PARP Inhibitors: Which One Should We Use?

Medical oncologists discuss the current FDA indications for the 3 available PARP inhibitors and expand on the data that [support] the choice of which agent to use, including factors such as toxicity profiles, cost, and convenience for patients with recurrent advanced ovarian cancer.